Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- LAG-3 Targeted Approach in Cancer Therapy
- Therapeutic Approaches for Novel LAG-3 Targeted Therapy
- Global LAG 3 Inhibitor Market Future Outlook
Download Report:
The emergence of novel immune checkpoint inhibitors including cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies have transformed the therapeutic landscape of several cancers. Immune checkpoint inhibitors have shown to significantly enhance survival rates in cancer patients. Despite this, there is no permanent cure of cancer which is boosting the research and development in cancer therapeutics. The promising response of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors has gained researchers interest in exploring additional immune checkpoints in tumor microenvironment.
Recent studies have identified several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on. Among all targets, LAG-3 represents one of the promising targets which have attracted scientists owing to its expression of wide range of solid tumors and hematological malignancies. The novel checkpoint, LAG-3 has shown synergy with PD-1 in multiple settings to inhibit immune response. Since its identification, it has been priority focus in immunotherapy as it enhances the efficacy of already approved PD-1/PD-L1 inhibitors in cancer patients.
In past few years, there has been explosion of interest and high-scale investments into this exciting space. The biotechnology companies are actively adopting strategic alliances including collaboration, partnerships, or join ventures to increase the investment in this sector. For instance, Immunetep has collaborated with Merck for a Phase I/IIa clinical trial to evaluate the feasibility, safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), when given in combination with bintrafusp alfa (M7824), an investigational bifunctional fusion protein immunotherapy. Furthermore, BeiGene and Najing Leads Biolab have announced worldwide license and collaboration agreement for development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, anti-LAG-3 antibody.
The pipeline for novel LAG-3 inhibitors is highly concentrated and is expected to flourish in market during the forthcoming years. Relatlimab developed by Bristol Myers Squibb is one of the most promising LAG-3 inhibitor in later stages of development. Recently in 2021, FDA has granted priority review to relatlimab and nivolumab for treatment of unresectable or metastatic melanoma. Apart from this, Immunetep has developed Eftilagimod Alpha (IMP321) which is also present in late stages for the management of metastatic breast cancer and head and neck squamous cell carcinoma. Apart from this, other candidates in development include LAG525, MGD013, MK4280, FS118, and others which are present in early stages of development.
Globally, there are more than 50 clinical trials ongoing which are evaluating the role of LAG-3 in various cancers. US has the highest number of ongoing clinical trials which is mainly due to presence of large pharmaceutical companies in the region. The pharmaceutical landscape has undergone a massive transformation with the emergence of new technologies, cost-effective, and more efficient manufacturing approaches. In addition, rising geriatric population and subsequent increase in prevalence of cancer is also increasing the demand of novel targeted drugs in the management. Apart from this, rising FDA designations including orphan status, priority review, breakthrough therapy, and others also boost the research and development sector in the region.
Surge in prevalence of cancer across geographies, high demand for ideal therapeutics for cancer treatment, development of favourable reimbursement policies, and rise in awareness of LAG-3 immune checkpoint inhibitors for the management of cancer due to positive results are the major factors boosting the growth of market. In addition, surge in geriatric population and increase in technological advancements in screening and diagnosing cancer will supplement the market growth.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366